Can cosentyx weaken the immune system over time?

Can Cosentyx weaken the immune system over time

Cosentyx blocks interleukin-17A, a signaling protein that drives inflammation in psoriasis, psoriatic arthritis, and ankylosing spondylitis. By interrupting this pathway the drug lowers the body’s ability to fight certain bacterial and fungal infections, and the prescribing information lists an increased risk of upper-respiratory infections, candidiasis, and rare but serious events such as tuberculosis reactivation.

Long-term clinical trials that followed patients for up to five years showed no progressive decline in overall immune function beyond the initial increase in infection rates. Serious infection rates remained stable rather than rising with continued use, and laboratory measures of immune cell counts did not show cumulative suppression.

How long does the immune-suppressing effect last after stopping Cosentyx

Interleukin-17A levels typically return to baseline within weeks after the last dose, and infection risk declines correspondingly. Patients who developed serious infections during treatment usually recovered once the drug was discontinued and appropriate antimicrobials were given.

What infections are patients most likely to report while taking Cosentyx

Upper-respiratory tract infections such as nasopharyngitis and sinusitis occur most often. Oral and genital candidiasis is also common, though usually mild and responsive to topical antifungals. Tuberculosis screening is required before starting therapy because latent TB can reactivate under IL-17 blockade.

Can other IL-17 inhibitors or TNF blockers cause similar immune effects

Secukinumab, ixekizumab, and brodalumab all share the IL-17 pathway blockade and carry comparable infection warnings. TNF inhibitors add risks for opportunistic infections and lymphoma that are not typical with IL-17 agents, while IL-17 drugs more selectively increase mucosal candidiasis.

What monitoring is recommended for long-term Cosentyx users

Doctors advise annual tuberculosis screening in high-risk patients, prompt evaluation of persistent fever or unexplained weight loss, and routine skin and mucosal exams for candidiasis. Vaccination status should be updated before treatment begins, because live vaccines are contraindicated while the drug is active.

When does the Cosentyx patent expire and what biosimilars are expected

The primary U.S. composition-of-matter patent for secukinumab is set to expire in 2029, with additional formulation and method-of-use patents extending coverage into the early 2030s. Biosimilar developers have already filed applications, but none have launched yet because of ongoing patent litigation.